Subbiah will report to Serge Stankovic, M.D., M.S.P.H., Acadia's president and be responsible for corporate medical affairs including medical strategy, scientific communications, and medical science liaison activities.
Subbiah is a neurologist with over 20 years of experience in the pharmaceutical industry and global health sector.
She has led the development and execution of medical and clinical research strategies in various therapeutic areas, including neurology, psychiatry, opioid addiction, pain, oncology, diabetes, urology, inflammation, respiratory, and infectious diseases.
Subbiah was most recently chief medical officer for Indivior Inc., with responsibility for pharmacovigilance and medical affairs globally.
She was also the company spokesperson at policy discussions including testifying at the presidential Commission on Combating Drug Addiction and Opioid Crisis and the hearing by the House Committee on Energy and Commerce on the opioid crisis.
During her previous tenure of over 15 years at Pfizer, Inc., she held various leadership roles in global medical affairs and led Pfizer's Global Access program to improve healthcare access for low-income populations in the developing world through approaches that were commercially viable and sustainable.
Acadia is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. Acadia has developed and commercialised the first and only medicine approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
Acadia also has ongoing clinical development efforts in additional areas with significant unmet need, including dementia-related psychosis, schizophrenia, major depressive disorder, and Rett syndrome.
Nuvalent commences NVL-655 phase 2 clinical trial in subjects with NSCLC and other solid tumours
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
GenSight Biologics reports business and financial update
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials